Cytomx Therapeutics Inc (CTMX)

$1.97

-0.18

(-8.37%)

Live

Insights on Cytomx Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 946.0K → 26.60M (in $), with an average increase of 27.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.99M → 837.0K (in $), with an average decrease of 72.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 18.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 248.2% return, outperforming this stock by 320.1%

Performance

  • $1.95
    $2.09
    $1.97
    downward going graph

    1.02%

    Downside

    Day's Volatility :6.7%

    Upside

    5.74%

    downward going graph
  • $1.04
    $2.86
    $1.97
    downward going graph

    47.21%

    Downside

    52 Weeks Volatility :63.64%

    Upside

    31.12%

    downward going graph

Returns

PeriodCytomx Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
29.13%
-1.1%
0.0%
6 Months
77.69%
6.7%
0.0%
1 Year
25.73%
3.2%
-0.7%
3 Years
-71.9%
15.2%
-21.6%

Highlights

Market Capitalization
145.6M
Book Value
- $0.7
Earnings Per Share (EPS)
-0.01
PEG Ratio
-1.8
Wall Street Target Price
2.9
Profit Margin
-0.56%
Operating Margin TTM
-2.28%
Return On Assets TTM
-1.75%
Return On Equity TTM
-5475.03%
Revenue TTM
101.2M
Revenue Per Share TTM
1.37
Quarterly Revenue Growth YOY
32.2%
Gross Profit TTM
53.2M
EBITDA
-4.3M
Diluted Eps TTM
-0.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.19
EPS Estimate Next Year
-0.37
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Hold
    7%Buy
    64%Hold
    28%Sell
Based on 14 Wall street analysts offering stock ratings for Cytomx Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
9
9
9
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 47.21%

Current $1.97
Target $2.90

Company Financials

FY18Y/Y Change
Revenue
59.5M
↓ 16.92%
Net Income
-84.6M
↑ 96.3%
Net Profit Margin
-142.19%
↓ 82.02%
FY19Y/Y Change
Revenue
57.5M
↓ 3.38%
Net Income
-102.2M
↑ 20.84%
Net Profit Margin
-177.84%
↓ 35.65%
FY20Y/Y Change
Revenue
100.4M
↑ 74.58%
Net Income
-32.9M
↓ 67.83%
Net Profit Margin
-32.77%
↑ 145.07%
FY21Y/Y Change
Revenue
69.6M
↓ 30.68%
Net Income
-80.6M
↑ 145.24%
Net Profit Margin
-115.92%
↓ 83.15%
FY22Y/Y Change
Revenue
53.2M
↓ 23.59%
Net Income
-97.3M
↑ 20.65%
Net Profit Margin
-183.02%
↓ 67.1%
FY23Y/Y Change
Revenue
101.2M
↑ 90.38%
Net Income
-569.0K
↓ 99.42%
Net Profit Margin
-0.56%
↑ 182.46%
Q3 FY22Q/Q Change
Revenue
16.9M
↓ 6.88%
Net Income
-22.7M
↓ 4.13%
Net Profit Margin
-133.9%
↓ 3.84%
Q4 FY22Q/Q Change
Revenue
946.0K
↓ 94.41%
Net Income
-26.6M
↑ 17.35%
Net Profit Margin
-2.8K%
↓ 2675.83%
Q1 FY23Q/Q Change
Revenue
23.5M
↑ 2384.04%
Net Income
-969.0K
↓ 96.35%
Net Profit Margin
-4.12%
↑ 2805.61%
Q2 FY23Q/Q Change
Revenue
24.7M
↑ 5.21%
Net Income
-1.1M
↑ 12.18%
Net Profit Margin
-4.4%
↓ 0.28%
Q3 FY23Q/Q Change
Revenue
26.4M
↑ 6.71%
Net Income
3.0M
↓ 375.25%
Net Profit Margin
11.34%
↑ 15.74%
Q4 FY23Q/Q Change
Revenue
26.6M
↑ 0.85%
Net Income
837.0K
↓ 72.03%
Net Profit Margin
3.15%
↓ 8.19%
FY18Y/Y Change
Total Assets
457.1M
↑ 14.95%
Total Liabilities
326.2M
↓ 0.46%
FY19Y/Y Change
Total Assets
341.3M
↓ 25.34%
Total Liabilities
290.2M
↓ 11.05%
FY20Y/Y Change
Total Assets
358.7M
↑ 5.09%
Total Liabilities
308.9M
↑ 6.44%
FY21Y/Y Change
Total Assets
339.4M
↓ 5.37%
Total Liabilities
250.0M
↓ 19.05%
FY22Y/Y Change
Total Assets
260.9M
↓ 23.13%
Total Liabilities
346.6M
↑ 38.64%
FY23Y/Y Change
Total Assets
205.2M
↓ 21.37%
Total Liabilities
252.6M
↓ 27.13%
Q3 FY22Q/Q Change
Total Assets
226.5M
↓ 12.92%
Total Liabilities
198.0M
↓ 6.32%
Q4 FY22Q/Q Change
Total Assets
260.9M
↑ 15.19%
Total Liabilities
346.6M
↑ 75.06%
Q1 FY23Q/Q Change
Total Assets
234.6M
↓ 10.07%
Total Liabilities
321.3M
↓ 7.32%
Q2 FY23Q/Q Change
Total Assets
209.2M
↓ 10.84%
Total Liabilities
294.2M
↓ 8.42%
Q3 FY23Q/Q Change
Total Assets
221.2M
↑ 5.73%
Total Liabilities
272.4M
↓ 7.41%
Q4 FY23Q/Q Change
Total Assets
205.2M
↓ 7.24%
Total Liabilities
252.6M
↓ 7.27%
FY18Y/Y Change
Operating Cash Flow
-75.5M
↓ 144.33%
Investing Cash Flow
5.9M
↓ 104.89%
Financing Cash Flow
139.6M
↑ 486.75%
FY19Y/Y Change
Operating Cash Flow
-140.5M
↑ 86.01%
Investing Cash Flow
79.7M
↑ 1244.94%
Financing Cash Flow
1.6M
↓ 98.83%
FY20Y/Y Change
Operating Cash Flow
5.3M
↓ 103.74%
Investing Cash Flow
-18.7M
↓ 123.49%
Financing Cash Flow
16.9M
↑ 938.29%
FY21Y/Y Change
Operating Cash Flow
-119.0M
↓ 2363.38%
Investing Cash Flow
22.5M
↓ 220.15%
Financing Cash Flow
110.2M
↑ 552.42%
FY22Y/Y Change
Operating Cash Flow
-110.8M
↓ 6.93%
Investing Cash Flow
22.5M
↑ 0.0%
Financing Cash Flow
648.0K
↓ 99.41%
Q3 FY22Q/Q Change
Operating Cash Flow
-33.8M
↓ 1.15%
Investing Cash Flow
-410.0K
↓ 0.49%
Financing Cash Flow
458.0K
↑ 1.55%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.4M
↓ 95.88%
Investing Cash Flow
-245.0K
↓ 40.24%
Financing Cash Flow
190.0K
↓ 58.52%
Q1 FY23Q/Q Change
Operating Cash Flow
9.3M
↓ 770.66%
Investing Cash Flow
-146.6M
↑ 59753.88%
Financing Cash Flow
317.0K
↑ 66.84%
Q2 FY23Q/Q Change
Operating Cash Flow
-25.2M
↓ 369.31%
Investing Cash Flow
26.0M
↓ 117.76%
Financing Cash Flow
317.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Cytomx Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cytomx Therapeutics Inc
Cytomx Therapeutics Inc
3.86%
77.69%
25.73%
-71.9%
-79.58%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cytomx Therapeutics Inc
Cytomx Therapeutics Inc
NA
NA
-1.8
-0.19
-54.75
-0.02
NA
-0.7
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.75
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.03
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.46
46.46
2.4
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.62
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cytomx Therapeutics Inc
Cytomx Therapeutics Inc
Hold
$145.6M
-79.58%
NA
-0.56%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.3B
140.93%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$564.6B
394.48%
46.46
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.5B
117.3%
28.57
36.68%

Institutional Holdings

  • Bvf Inc

    9.74%
  • TANG CAPITAL MANAGEMENT LLC

    9.52%
  • Vanguard Group Inc

    7.24%
  • Acadian Asset Management LLC

    3.91%
  • Renaissance Technologies Corp

    1.96%
  • LAURION CAPITAL MANAGEMENT LP

    1.75%

Corporate Announcements

  • Cytomx Therapeutics Inc Earnings

    Cytomx Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o

Organization
Cytomx Therapeutics Inc
Employees
120
CEO
Dr. Sean A. McCarthy DPHIL
Industry
Health Technology

FAQs